Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MDLast reviewed:
Molecular Testing in Cancer
Biomarkers that guide therapy — not good/bad labels
More tests are not always better — the question comes first.
Molecular and biomarker tests describe tumor or hereditary features that guide targeted drugs, immunotherapy, surgical sequencing, and family screening. Examples include MMR/MSI, RAS/BRAF, HER2, PD-L1, NTRK fusions, and CLDN18.2 protein expression — not all are “mutations.” Somatic tumor testing answers treatment questions; germline testing answers family-risk questions — mixing them confuses patients. A positive targetable result does not erase stage, fitness, or surgical judgment. Ordering panels without a clinical question wastes time and can delay necessary care.
- Hero figure: molecular testing in cancer as an overview.
- Related figures explain why biomarkers and panel testing guide oncology decisions.
Six terms before you read further
- Germline
- Inherited DNA in every cell — answers family-risk questions
- Somatic
- Change only in tumor tissue — answers treatment questions
- Biomarker
- A molecular feature that may select a therapy path
- MMR/MSI
- Repair-pathway status; may open immunotherapy and Lynch work-up
- Targeted therapy
- Drugs matched to a specific biomarker
- NGS (panel)
- Sequencing many genes at once
Educational figures
Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.
Overview Colorectal Gastric Breast
What to know
Six terms before you read further
Reports use many abbreviations. Start with these six — detail below is layered, not removed.
- Germline: inherited DNA in every cell — answers family-risk questions
- Somatic: change only in tumor tissue — answers treatment questions
- Biomarker: a molecular feature that may select a therapy path
- MMR/MSI: repair-pathway status; may open immunotherapy and Lynch work-up
- Targeted therapy: drugs matched to a specific biomarker
- NGS (panel): sequencing many genes at once
- Key note inside
Which results actually change treatment?
A negative result is also information: that drug path is not appropriate.A positive result rarely cancels urgent surgery by itself; most decisions land at the systemic-therapy step. Quick map:
- Colorectal dMMR/MSI-H → immunotherapy; Lynch pathway
- Colorectal RAS/BRAF → anti-EGFR eligibility; prognosis context
- Gastric HER2 / CLDN18.2 / PD-L1 → advanced-disease drug selection
- Breast ER/PR/HER2 → endocrine, anti-HER2, chemotherapy sequencing
- Pancreas germline BRCA/PALB2 → platinum sensitivity, PARP options; family screening
- Rare NTRK fusion, BRAF V600E, MSI-H (any tumor) → targeted options when approved
MMR / MSI
Can open immunotherapy discussions and Lynch evaluation. Often considered early in colorectal diagnosis.
Targetable changes are different classes
Mutations, amplifications, fusions, and protein expression are not interchangeable words.
- RAS/BRAF → often mutations
- HER2 → amplification/expression
- NTRK → usually fusion
- CLDN18.2 → protein expression
- Key note inside
Limits of testing
A test does not equal cure; stage, performance status, and resectability still matter.
- Key note inside
Do not delay emergencies
Necessary emergency surgery is not postponed waiting for every molecular result; systemic steps can follow when results return.
How we use reports together
Pathology, imaging, and biomarkers are read as one story in tumor board — not as competing scores.
What happens next
Biomarkers answer specific treatment and hereditary questions
- 1
Molecular Testing Overview
Biomarkers answer specific treatment and hereditary questions
Read this chapter - 2
Molecular Testing in Colorectal Cancer
MMR/MSI, RAS/BRAF, and selected HER2/NTRK contexts
Read this chapter - 3
Molecular Testing in Gastric Cancer
HER2, PD-L1, CLDN18.2, and MSI/MMR timing
Read this chapter - 4
Molecular Testing in Breast Cancer
ER/PR/HER2 foundations and germline BRCA framework
Read this chapter - 5
Molecular Testing in Pancreatic Cancer
Germline testing is discussed for most patients; tumor profiling in advanced disease
Read this chapter - 6
Hereditary Cancers
Lynch, BRCA, FAP, CDH1, and genetic counseling in surgical patient language
Read this chapter
Evidence
Scientific sources
Show sources · 4Guideline bases for when molecular / NGS and MMR-MSI testing change decisions — not “every test for everyone.”
Evidence
Scientific sources
- Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024 — ESMO Precision Medicine Working GroupESMO · 2024 · DOI: 10.1016/j.annonc.2024.04.005Open source
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEuropean Society for Medical Oncology (ESMO) · 2023 · DOI: 10.1016/j.annonc.2022.10.003Open source
- CAP / AMP / ASCO guideline context — MMR/MSI testing in colorectal cancerCollege of American Pathologists (guideline ecosystem) · Current pathology guidelinesOpen source
- NCCN Clinical Practice Guidelines in Oncology: Colon CancerNational Comprehensive Cancer Network (NCCN) · Current versionOpen source
Source list last checked: 21 August 2026. (Page content review date may appear separately above.)
Appointment / info
Bring pathology reports — we can map which tests matter for your tumor type and stage.
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.